Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Zhaoke Ophthalmology's operating assets for the quarter that ended in Dec. 2025 was €118.16 Mil. Zhaoke Ophthalmology's operating liabilities for the quarter that ended in Dec. 2025 was €8.13 Mil. Zhaoke Ophthalmology's Total Assets for the quarter that ended in Jun. 2025 was €249.78 Mil. Therefore, Zhaoke Ophthalmology's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.44.
Zhaoke Ophthalmology Scaled Net Operating Assets Related Terms
Zhaoke Ophthalmology Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Zhaoke Ophthalmology's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhaoke Ophthalmology Scaled Net Operating Assets Chart
FRA:9FX vs VRTX, REGN, MRNA: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Zhaoke Ophthalmology's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhaoke Ophthalmology Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Zhaoke Ophthalmology's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.44 mean?
Zhaoke Ophthalmology (FRA:9FX) has a Scaled Net Operating Assets of 0.44 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Zhaoke Ophthalmology and its competitors.
Is Zhaoke Ophthalmology's Scaled Net Operating Assets too high?
Zhaoke Ophthalmology's current Scaled Net Operating Assets is 0.44. Overall, Zhaoke Ophthalmology has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Zhaoke Ophthalmology's Scaled Net Operating Assets compare to VRTX and REGN?
Zhaoke Ophthalmology's Scaled Net Operating Assets of 0.44 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Zhaoke Ophthalmology and its competitors. Zhaoke Ophthalmology's current Scaled Net Operating Assets is 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhaoke Ophthalmology stock overvalued right now?
Zhaoke Ophthalmology (FRA:9FX) has a current Scaled Net Operating Assets of 0.44. The stock's GF Value™ is €0.27, compared to a current price of €0.26 — trading 4.4% below its estimated fair value. The current Scaled Net Operating Assets is 0.44. Zhaoke Ophthalmology's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Zhaoke Ophthalmology (FRA:9FX), the current Scaled Net Operating Assets is 0.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhaoke Ophthalmology (FRA:9FX) Overvalued in 2026?
Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued.
The current stock price of €0.26 is trading 4.4% below its estimated GF Value™ of €0.27.
Key valuation signals for FRA:9FX:
Scaled Net Operating Assets: 0.44
GF Value™: €0.27 vs. price of €0.26 (4.4% below fair value)
No single metric tells the full story. See the FRA:9FX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score
Get the complete analysis for FRA:9FX
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9FX has been successfully added to your 
